Updates are available Correction dated 2024-06-28
Click to view Correction: https://doi.org/10.1007/s10620-024-08510-w
-
Authors
Saitta, Daniel
Henneken, Lee M.
Apputhurai, Pragalathan
Chen Yi Mei, Swee Lin
Tye-Din, Jason A.
-
Funding
Funding for this research was provided by:
Tillotts Pharma
University of Melbourne
- License Information
-
More Information
Article History
Received: 9 December 2023
Accepted: 10 April 2024
First Online: 29 April 2024
Change Date: 28 June 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10620-024-08510-w
Declarations
:
: This study was funded by a research grant provided by Tillotts Pharma. JT-D has privately or via his institute been a consultant or advisory board member for Anatara Lifesciences, Anokion, Barinthus Biotherapeutics, Codexis, Chugai Pharmaceuticals, Equillium, EVOQ Therapeutics, IM Therapeutics, Janssen, Kallyope, Mozart Therapeutics, Janssen, Teva, and Topas and has received honoraria from Takeda and research funding from Barinthus Biotherapeutics, Chugai Pharmaceuticals, Codexis, DBV Technologies, EVOQ Therapeutics, Kallyope, Novoviah Pharmaceuticals, Topas, and Tillotts Pharma. He is an inventor on patents relating to the use of gluten peptides in CeD diagnosis and treatment.
: The study was approved by the Human Research Ethics Committee of Melbourne Health, Australia (2021.222).
